Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer

A targeted treatment with off-target risks

This article has been updated

It emerges that blood-cancer-targeting drugs that block a tumour-survival pathway also activate a mutation-causing enzyme in mice and in human cells. This might have implications for the clinical use of these drugs. See Letter p.489

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Inhibition of a B-cell-receptor signalling pathway might increase the number of harmful mutations.

Change history

  • 22 February 2017

    A new reference 10 has been added, in acknowledgement of the fact that this paper was the first to report that PI3Kδ suppresses expression of AID.

Notes

  1. 1.

    See all news & views

References

  1. 1

    Luo, J., Solimini, N. L. & Elledge, S. J. Cell 136, 823–837 (2009).

    CAS  Article  Google Scholar 

  2. 2

    Compagno, M. et al. Nature 542, 489–493 (2017).

    ADS  CAS  Article  Google Scholar 

  3. 3

    Wiestner, A. Haematologica 100, 1495–1507 (2015).

    CAS  Article  Google Scholar 

  4. 4

    Ten Hacken, E. & Burger, J. A. Clin. Cancer Res. 20, 548–556 (2014).

    CAS  Article  Google Scholar 

  5. 5

    Okkenhaug, K. & Burger, J. A. Curr. Top. Microbiol. Immunol. 393, 123–142 (2016).

    CAS  PubMed  Google Scholar 

  6. 6

    Byrd, J. C. et al. N. Engl. J. Med. 369, 32–42 (2013).

    CAS  Article  Google Scholar 

  7. 7

    Furman, R. R. et al. N. Engl. J. Med. 370, 997–1007 (2014).

    CAS  Article  Google Scholar 

  8. 8

    Smith, M. R. Expert Opin. Pharmacother. 16, 1879–1887 (2015).

    CAS  Article  Google Scholar 

  9. 9

    Lamanna, N. & O'Brien, S. Hematol. Am. Soc. Hematol. Educ. Prog. 2016, 137–145 (2016).

    Article  Google Scholar 

  10. 10

    Omori, S. A. et al. Immunity 25, 545–557 (2006).

    CAS  Article  Google Scholar 

  11. 11

    Zhang, T. et al. J. Allergy Clin. Immunol. 122, 811–819 (2008).

    CAS  Article  Google Scholar 

  12. 12

    Chandra, V., Bortnick, A. & Murre, C. Trends Immunol. 36, 527–535 (2015).

    CAS  Article  Google Scholar 

  13. 13

    Fruman, D. A., Satterthwaite, A. B. & Witte, O. N. Immunity 13, 1–3 (2000).

    CAS  Article  Google Scholar 

  14. 14

    O'Brien, S. M. et al. 58th ASH Annu. Meet. Expos. Abstr. 233 (2016); see go.nature.com/2kssjo8

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to David A. Fruman.

Ethics declarations

Competing interests

The authors declare competing financial interests. See online article for details.

Related links

Related links

Related links in Nature Research

Cancer: A gene-expression profile for leukaemia

Cancer genomics: Spot the difference

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fruman, D., O'Brien, S. A targeted treatment with off-target risks. Nature 542, 424–425 (2017). https://doi.org/10.1038/nature21504

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing